What About All the Recent “Negative” FFR Trials? - 08/11/23
Résumé |
During the past 30 years, fractional flow reserve (FFR) has moved from animal models to class IA recommendations in guidelines. However, the FLOWER-MI, RIPCORD-2, FUTURE, and FAME 3 trials in 2021 were “negative”—has FFR exceeded its expiration date? We critically examine these randomized trials in order to draw insights not just about FFR but also about study design and interpretation. Are all randomized trials created equal? No, rather we must focus on discordant decisions between angiography and FFR and highlight clinical endpoints that can be improved by percutaneous coronary intervention instead of medical therapy.
Le texte complet de cet article est disponible en PDF.Keywords : Fractional flow reserve, Randomized controlled trial, Percutaneous coronary intervention, Coronary artery bypass grafting
Plan
| This article originally appeared in Interventional Cardiology Clinics, Volume 12 Issue 1, January 2023. |
Vol 42 - N° 1
P. 31-39 - février 2024 Retour au numéro
Article précédent
- Is Coronary Physiology Assessment Valid in Special Circumstances? : Aortic Stenosis, Atrial Fibrillation, Left Ventricular Hypertrophy, and Other
- David M. Tehrani, Arnold H. Seto
- Using Physiology Pullback for Percutaneous Coronary Intervention Guidance : Is this the Future?
- Sukhjinder Singh Nijjer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?